135 related articles for article (PubMed ID: 23719501)
1. [Serum sclerostin levels and metabolic bone diseases].
Yamauchi M; Sugimoto T
Clin Calcium; 2013 Jun; 23(6):877-83. PubMed ID: 23719501
[TBL] [Abstract][Full Text] [Related]
2. Comparisons of serum sclerostin levels among patients with postmenopausal osteoporosis, primary hyperparathyroidism and osteomalacia.
Kaji H; Imanishi Y; Sugimoto T; Seino S
Exp Clin Endocrinol Diabetes; 2011 Jul; 119(7):440-4. PubMed ID: 21667439
[TBL] [Abstract][Full Text] [Related]
3. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients.
Cejka D; Jäger-Lansky A; Kieweg H; Weber M; Bieglmayer C; Haider DG; Diarra D; Patsch JM; Kainberger F; Bohle B; Haas M
Nephrol Dial Transplant; 2012 Jan; 27(1):226-30. PubMed ID: 21613383
[TBL] [Abstract][Full Text] [Related]
4. Sclerostin and DKK1 in primary hyperparathyroidism.
Viapiana O; Fracassi E; Troplini S; Idolazzi L; Rossini M; Adami S; Gatti D
Calcif Tissue Int; 2013 Apr; 92(4):324-9. PubMed ID: 23430197
[TBL] [Abstract][Full Text] [Related]
5. High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the Center of Excellence for Osteoporosis Research Study.
Ardawi MS; Rouzi AA; Al-Sibiani SA; Al-Senani NS; Qari MH; Mousa SA
J Bone Miner Res; 2012 Dec; 27(12):2592-602. PubMed ID: 22836717
[TBL] [Abstract][Full Text] [Related]
6. [Wnt signaling and bone metabolic diseases.].
Yamauchi M; Sugimoto T
Clin Calcium; 2019; 29(3):329-336. PubMed ID: 30814378
[TBL] [Abstract][Full Text] [Related]
7. High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density.
Voskaridou E; Christoulas D; Plata E; Bratengeier C; Anastasilakis AD; Komninaka V; Kaliontzi D; Gkotzamanidou M; Polyzos SA; Dimopoulou M; Terpos E
Horm Metab Res; 2012 Nov; 44(12):909-13. PubMed ID: 22581647
[TBL] [Abstract][Full Text] [Related]
8. Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes.
Ardawi MS; Akhbar DH; Alshaikh A; Ahmed MM; Qari MH; Rouzi AA; Ali AY; Abdulrafee AA; Saeda MY
Bone; 2013 Oct; 56(2):355-62. PubMed ID: 23845326
[TBL] [Abstract][Full Text] [Related]
9. Clinical and endocrine correlates of circulating sclerostin levels in patients with type 1 diabetes mellitus.
Neumann T; Hofbauer LC; Rauner M; Lodes S; Kästner B; Franke S; Kiehntopf M; Lehmann T; Müller UA; Wolf G; Hamann C; Sämann A
Clin Endocrinol (Oxf); 2014 May; 80(5):649-55. PubMed ID: 24237244
[TBL] [Abstract][Full Text] [Related]
10. Serum sclerostin in alcoholics: a pilot study.
González-Reimers E; Martín-González C; de la Vega-Prieto MJ; Pelazas-González R; Fernández-Rodríguez C; López-Prieto J; Alvisa-Negrín J; Santolaria-Fernández F
Alcohol Alcohol; 2013; 48(3):278-82. PubMed ID: 23296214
[TBL] [Abstract][Full Text] [Related]
11. Determinants of serum sclerostin in healthy pre- and postmenopausal women.
Ardawi MS; Al-Kadi HA; Rouzi AA; Qari MH
J Bone Miner Res; 2011 Dec; 26(12):2812-22. PubMed ID: 21812027
[TBL] [Abstract][Full Text] [Related]
12. Association of circulating sclerostin levels with fat mass and metabolic disease--related markers in Japanese postmenopausal women.
Urano T; Shiraki M; Ouchi Y; Inoue S
J Clin Endocrinol Metab; 2012 Aug; 97(8):E1473-7. PubMed ID: 22639287
[TBL] [Abstract][Full Text] [Related]
13. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women.
Mirza FS; Padhi ID; Raisz LG; Lorenzo JA
J Clin Endocrinol Metab; 2010 Apr; 95(4):1991-7. PubMed ID: 20156921
[TBL] [Abstract][Full Text] [Related]
14. Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls.
van Lierop AH; Witteveen JE; Hamdy NA; Papapoulos SE
Eur J Endocrinol; 2010 Nov; 163(5):833-7. PubMed ID: 20817762
[TBL] [Abstract][Full Text] [Related]
15. Suppression of Sclerostin and Dickkopf-1 levels in patients with fluorine bone injury.
Wang W; Xu J; Liu K; Liu X; Li C; Cui C; Zhang Y; Li H
Environ Toxicol Pharmacol; 2013 May; 35(3):402-7. PubMed ID: 23467116
[TBL] [Abstract][Full Text] [Related]
16. Sclerostin blood levels before and after kidney transplantation.
Bonani M; Rodriguez D; Fehr T; Mohebbi N; Brockmann J; Blum M; Graf N; Frey D; Wüthrich RP
Kidney Blood Press Res; 2014; 39(4):230-9. PubMed ID: 25118597
[TBL] [Abstract][Full Text] [Related]
17. Circulating fibroblast growth factor-23 increases following intermittent parathyroid hormone (1-34) in postmenopausal osteoporosis: association with biomarker of bone formation.
Sridharan M; Cheung J; Moore AE; Frost ML; Fraser WD; Fogelman I; Hampson G
Calcif Tissue Int; 2010 Nov; 87(5):398-405. PubMed ID: 20838781
[TBL] [Abstract][Full Text] [Related]
18. Physical activity in relation to serum sclerostin, insulin-like growth factor-1, and bone turnover markers in healthy premenopausal women: a cross-sectional and a longitudinal study.
Ardawi MS; Rouzi AA; Qari MH
J Clin Endocrinol Metab; 2012 Oct; 97(10):3691-9. PubMed ID: 22865898
[TBL] [Abstract][Full Text] [Related]
19. Sclerostin in institutionalized elderly women: associations with quantitative bone ultrasound, bone turnover, fractures, and mortality.
Amrein K; Dobnig H; Wagner D; Piswanger-Sölkner C; Pieber TR; Pilz S; Tomaschitz A; Dimai HP; Fahrleitner-Pammer A
J Am Geriatr Soc; 2014 Jun; 62(6):1023-9. PubMed ID: 24779429
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with serum soluble inhibitors of Wnt-β-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis.
Yamada S; Tsuruya K; Tokumoto M; Yoshida H; Ooboshi H; Kitazono T
Nephrology (Carlton); 2015 Sep; 20(9):639-45. PubMed ID: 25974190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
